Intravitreal Aflibercept for the Treatment of Treatment Resistant Diabetic Macular Oedema

This study is testing a drug called aflibercept (injected into the eye) for patients with diabetic macular oedema — a condition where fluid builds up in the back of the eye due to diabetes, causing blurry vision or vision loss. Some patients do not respond well to the usual eye injection treatments. This study will evaluate whether aflibercept can improve vision and reduce swelling in these treatment-resistant cases. You may be eligible if: - You are 18 years or older - You have type 1 or type 2 diabetes - You have swelling in the central part of your retina (diabetic macular oedema) that has not improved after at least 4 previous anti-VEGF eye injections over at least 6 months - Your vision in the affected eye is between a Snellen equivalent of 6/6 and 6/60 You may NOT be eligible if: - You are pregnant or breastfeeding - You are a pre-menopausal woman not using contraception - You have had eye surgery, laser treatment, or a vitrectomy recently in that eye - Your blood sugar is very poorly controlled (HbA1c above 12%) - You have had a recent stroke or heart attack (within 3 months) - You have uncontrolled glaucoma or high blood pressure Talk to your doctor about whether this trial might be right for you.